US pharmaceutical industry lobbies against broad restrictions on China operations

Pharmaceutical companies are actively lobbying to mitigate the impact of potential US legislative restrictions on business operations in China. The effort highlights industry concerns over supply chain dependencies and market access amid escalating geopolitical tensions between Washington and Beijing.